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Abstract
Objectives—Esophageal dilation is commonly performed in eosinophilic esophagitis (EoE), but 
there are few long-term data. The aims of this study were to assess the safety and long-term 
efficacy of esophageal dilation in a large cohort of EoE cases and determine the frequency and 
predictors of requiring multiple dilations.
Methods—We conducted a retrospective cohort study in the University of North Carolina EoE 
clinicopathological database from 2002-2014. Included subjects met consensus diagnostic criteria 
for EoE. Clinical, endoscopic, and histologic features were extracted, as were dilation 
characteristics (dilator type, change in esophageal caliber, total number of dilations) and 
complications. Patients with EoE who had undergone dilation were compared to those who did not 
and also stratified by whether they required single or multiple dilations.
Results—Of 509 EoE patients, 164 were dilated a total of 486 times. Those who underwent 
dilation had a longer duration of symptoms prior to diagnosis (11.1 vs. 5.4 yrs, p<0.001). 95 
patients (58%) required >1 dilation (417 dilations total, mean of 4.4 ± 4.3 per patient). The only 
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predictor of requiring multiple dilations was a smaller baseline esophageal diameter. Dilation was 
tolerated well, with no major bleeds, perforations, or deaths. The overall complication rate was 
5%, primarily due to post-procedural pain. Of 164 individuals dilated, a majority (58%, or 95/164) 
required a second dilation. Of these individuals, 75% required dilation within 1 year.
Conclusions—Dilation in EoE is well-tolerated, with a very low risk of serious complications. 
Patients with long-standing symptoms prior to diagnosis are likely to require dilation. More than 
half of those dilated will require multiple dilations, often needing a second procedure within one 
year. These findings can be used to counsel patients with fibrostenotic complications of EoE.
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Introduction
Eosinophilic esophagitis is a recently recognized condition characterized clinically by 
symptoms of esophageal dysfunction and histologically by esophageal eosinophilia, after 
excluding secondary causes (1-3). Common symptoms are dysphagia, food impaction, chest 
pain, abdominal pain, and vomiting (2, 4-6). The prevalence of EoE has markedly increased 
over the past two decades (7-13) and it is now a major contributor to health care costs (14).
Chronic eosinophilic inflammation is known to cause a number of mechanical complications 
in the esophagus secondary to fibrosis (15-17). This inflammatory cascade results in 
esophageal rings, narrowing, strictures, and mucosal fragility, termed crêpe-paper mucosa 
(18-23), which lead to clinical manifestations of dysphagia as well as food impaction, of 
which EoE is now the most common cause (24, 25). Although some anti-inflammatory 
therapies may help improve fibrosis at the microscopic level (26, 27), esophageal dilation 
has become an accepted mechanical therapy in EoE (1, 6, 20, 23, 28-33) and can be an 
effective treatment for these symptoms (29, 31, 33-36). However, published experience to 
date with dilation remains somewhat limited (37, 38), and there are few long-term outcomes 
known. In our clinical experience, many EoE patients require multiple dilations over time, 
but this not been extensively investigated.
The aims of this study were to assess the safety, efficacy, and tolerability of esophageal 
dilation in a large cohort of EoE cases, assess outcomes, and determine the frequency and 
predictors of requiring multiple dilations.
Methods
We conducted a retrospective cohort study using the University of North Carolina EoE 
clinicopathological database. The details of this database have been described previously 
(23, 39-42). The database contains EoE cases of all ages from March 2002 through June 
2014. Briefly, included patients met consensus guidelines for a new diagnosis of EoE (1, 2). 
Patients were required to have ≥ 15 eos in at least one high-power field (HPF) despite 8 
weeks of proton pump inhibitor therapy. Patients had to have one or more typical symptoms 
of esophageal dysfunction, such as dysphagia, heartburn, food impaction, or feeding 
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intolerance, and other causes of esophageal eosinophilia were excluded. Only incident, not 
prevalent, cases were included.
Clinical information was extracted from the medical record on both a per-patient and per-
dilation basis to determine demographics, endoscopic findings, number of dilations 
performed, initial and final esophageal diameter, type of dilator used (wire-guided bougie 
[Savary] vs through-the-scope [TTS] balloon), and any concomitant medical or dietary 
treatment. Patients were studied from the time they were diagnosed with EoE forward. If a 
stricture was present at diagnosis, dilation was performed if indicated. Therefore, dilation 
could be done before, after, or concomitantly with topical corticosteroid or dietary 
elimination therapy (1, 3). Dilations were performed by the attending gastroenterologist, 
who also selected the dilation technique based on their preference and the clinical scenario. 
In general, if a focal stricture was identified, standard TTS balloon technique (stationary 
dilation) was used. If there was a markedly narrowed esophagus or a severe stricture such 
that the adult upper scope would not pass, then typically a neonatal scope was used and 
Savary dilation was performed. If diffuse narrowing or multifocal strictures were seen, the 
balloon pull-through technique could be utilized, at the discretion of the endoscopist. In 
brief, this technique involves inflation of a TTS balloon across the GEJ, followed by slow 
withdrawal of the endoscope and balloon from distal to proximal esophagus (43). If 
resistance is encountered, the balloon is positioned across that area and slowly reinflated. If 
no resistance if encountered, the balloon is deflated and the esophagus is inspected for 
mucosal trauma. If no trauma is seen, the process is repeated with the next largest balloon 
diameter.
A repeat dilation was considered planned if specific follow-up was scheduled; it was 
unplanned if the indication was for recurrent symptoms after prior successful treatment. In 
general, planned follow-up was scheduled for patients with tight strictures or a diffusely 
narrowed esophagus. In this setting a patient was scheduled for repeat dilation every 4-6 
weeks until a symptomatic response was achieved, and the esophagus had been dilated to a 
diameter of at least 15mm. However, the timing could vary based on the severity of the 
stricture and the concomitant EoE treatment, with shorter intervals for more severe 
strictures.
Complications of dilation (esophageal pain/discomfort, chest pain requiring medical 
attention or hospitalization, any ER visit, bleeding, perforation, or death) were also assessed. 
Post-procedure discomfort was defined as chest pain for which analgesics were prescribed 
or an ER visit was needed. Bleeding was defined as intra- or post-procedural bleeding for 
which the patient required endoscopic or other therapy or management in a health care 
facility. Perforation was defined as extravasation of contrast material on esophagogram or 
the presence of pneumomediastinum on CT scan. Measurements of esophageal luminal 
diameter were taken from the endoscopists’ report; if it was not clearly stated, it was 
extrapolated from the diameter of the dilators used. This method has been used in prior 
studies of dilation in EoE (29, 33), with the understanding that estimating the esophageal 
lumen can be difficult based on visual assessment alone (44). Information on symptom 
response to dilation was obtained from medical records. Because this was a retrospective 
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study, symptom response was dichotomized (yes/no) based on patient global report, a 
method that we have previously used successfully (41, 42).
Statistical analysis was performed with Stata version 13 (Statacorp, College Station, TX) 
using data collected on a per-patient level as well as a per-dilation level. Descriptive 
statistics were used to summarize data, and bivariate analyses were performed using 
Student’s t-test, chi-square, or Fisher’s exact test where appropriate to compare EoE cases 
who did and did not require dilation. Multiple logistic regression was used to determine 
predictors of needing dilation. We also compared results of patients undergoing balloon vs 
Savary dilation, patients who received a single dilation compared with those who required 
multiple dilations, and characteristics stratified by provider type (senior author vs other 
endoscopists). This study was approved by the University of North Carolina Institutional 
Review Board.
Results
Patient and dilation characteristics
Of 509 patients identified with an incident diagnosis EoE, 164 (32%) required esophageal 
dilation. A total of 486 dilations were performed (mean 3.0 ± 3.7 dilations per patient). For 
191 of the dilations (40%) patients were on a concomitant topical steroid, and for 73 (15%) 
patients were on concomitant dietary elimination therapy. The median follow-up time was 
15.1 months (IQR: 5-48 mos), and ranged from 0 mos to 13.5 years.
Compared to EoE cases who did not require dilation, those who underwent dilation were 
more likely to be white (89% vs. 79% p<0.001) and have a longer duration of symptoms 
prior to diagnosis (11.1 vs. 5.4 yrs, p <0.001) (Table 1). Clinical factors associated with 
requiring dilation included dysphagia (OR 21.5; 95% CI 9.26-50.0), food impaction (OR 
2.61; 1.75-3.90), absence of heartburn (OR 1.75; 1.17-2.65), and absence of abdominal pain 
(OR 4.25; 2.30-7.87). Endoscopic factors associated with receiving dilation included the 
presence of rings (OR 5.59; 3.71-8.42) and lack of a normal baseline endoscopy (OR 14.42; 
4.46-46.5). In the multivariate regression model which included age at diagnosis, dysphagia, 
the presence of rings on endoscopy, an abnormal baseline endoscopy, and the absence of 
heartburn, the presence of dysphagia was the strongest predictor of requiring esophageal 
dilation (OR 8.45; 3.45-20.7). Other factors independently associated with dilation were 
absence of heartburn (OR 1.79; 1.08-2.96), the presence of rings (OR 1.87; 1.10-3.17) and 
an abnormal baseline endoscopy (OR 6.62; 1.42-30.9). Of note, in both bivariate and 
multivariate analyses, the baseline eosinophil count did not predict dilation.
Safety
Post-dilation complications identified included hospitalization in 2 patients (0.4%), pain 
requiring medical attention in 21 (4%), and emergency department evaluation in 5 (1%) 
(Table 2). Both hospitalized patients were treated for aspiration pneumonia with antibiotics 
and were discharged in good condition. There were no major bleeds, perforations, or deaths. 
The overall complication rate per procedure was 5%. Stratified by type of dilation, those 
dilated with through-the-scope (TTS) balloon dilators tended to have fewer complications 
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(Table 3), but this was not significant (4% vs 10%; p=0.10). Information on post-dilation 
discomfort was available for 46% (223/486) of procedures, and in these cases, 41% (91/223) 
reported some degree of discomfort following dilation. The frequency of discomfort was not 
different for bougie vs TTS dilators (44% vs. 40%, p=0.57).
Efficacy and dilation technique
TTS dilators were used in 81% of procedures, and wire-guided bougie dilators were used in 
19%. Overall, between each patient’s first and last dilations, esophageal diameter improved 
from 12.5 ± 3.0 mm to 15.2 ± 2.9 mm (Table 2). On a per-patient basis, information on 
symptomatic response was available for 124 patients. Of these, 108 (87%) had a 
symptomatic response to dilation overall. On a per-procedure basis, symptom response 
information was available for 153 procedures, and patients reported improved symptoms 
after 130 (85%). Symptom response was similar for those on either dietary or topical steroid 
therapy (88%) compared to those on neither therapy (81%). Of the 45% of patients not on 
concomitant medical or dietary treatment for EoE at the time of dilation, one-third of 
dilations occurred on high-dose PPI alone at the time of EoE diagnosis, and for another third 
patients had stopped EoE medications prior to their dilation due to non-adherence, expense, 
or because they had run out. There were few differences in outcomes between patients who 
had balloon vs bougie dilation (Table 3).
Half of the patients (n=82) were dilated by a single provider (ESD). When comparing this 
sub-group to those treated by the other endoscopists, there were few major differences in 
baseline clinical, endoscopic, or histologic features (data not shown). A total of 248 dilations 
were performed by the single provider, compared with 238 for other providers, and 
techniques and dilation characteristics were largely similar overall (Supplemental Table 1).
Multiple dilations and dilation timing
At total of 95 patients (58%) required multiple dilations. Those undergoing multiple 
dilations comprised 417 dilations, for a mean of 4.4 ± 4.3 dilations per patient; 36 patients 
(22%) required 4 or more dilations. The median follow-up time in this group was 31 months 
(IQR: 12-62 mos).
There were few clinical differences between those undergoing multiple dilations and a 
single dilation (Table 4). However, those who received multiple dilations had a smaller 
esophageal diameter prior to dilation (11.3mm vs. 12.5mm, p=0.01) and ultimately achieved 
greater increases in esophageal diameter (4.9 vs. 3.0 mm, p<0.001). However, on a per-
dilation basis the gains were modest. For example, these individuals achieve only a 1.1mm 
mean increase per session, compared to 3.0mm in those dilated once. Those with multiple 
dilations were also more likely to have a symptomatic response to dilation (94% vs. 80%, 
p=0.014) and to be dilated using bougie dilators (35% vs. 19%, p=0.02).
These patients also had frequent need for dilation, as the median interval between dilations 
was 3 months (IQR: 2-8 mos). The median time from the first to the second dilation was 4 
months (IQR: 2-11 mos), and the median time from first to last dilation was 14 months 
(IQR: 5-42 mos). Overall, 75% (73/95) of those requiring multiple dilations, and 45% of the 
entire cohort (75/164), underwent a second dilation within one year. Of those receiving 
Runge et al. Page 5
Am J Gastroenterol. Author manuscript; available in PMC 2017 February 01.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
multiple dilations, 213 dilations (68%) were planned for continued stricture treatment; 98 
dilations (32%) were provoked by patient symptoms. 60% of those receiving planned 
dilations were on medications; among those with unplanned dilations, only 45% were on 
medical therapy. Information on the temporality of patients’ second and third dilations is 
shown in Figure 1. Additionally, as the number of dilations required increased, the intervals 
between dilation became shorter. Those who required three or fewer dilations had 
significantly longer dilation-free periods than those who required 4 or more (33 vs. 7 
months, p=0.01).
Discussion
Esophageal dilation is frequently utilized in EoE to treat complications of longstanding 
fibrostenotic disease such as rings, strictures, and a narrow-caliber esophagus (29, 31-33, 
36-38). The aims of this study were to update the safety, efficacy, and tolerability of 
esophageal dilation in a large cohort of EoE cases as well as to assess outcomes, particularly 
related to the frequency and predictors of requiring multiple dilations. Among our large 
cohort of EoE patients, about one-third required esophageal dilation. In addition, the 
majority of these individuals needed multiple dilations, with more than one-fifth requiring 4 
or more. This implies that once esophageal remodeling has occurred in EoE, it is not easily 
reversible even by mechanical means. We also found that over the course of nearly 500 
dilations, a number that increases the published experience by approximately 50%, the 
procedure was both safe and effective.
Previous studies have shown that between one-quarter and one-third of adult EoE patients 
require esophageal dilation (29, 31, 33, 36, 45). In our cohort, individuals received 3 
dilations on average per patient, which is higher than the average of 1.2 – 2.2 dilations per 
patient reported in the literature (29, 31, 33, 36). However, a recent abstract showed that in 
some EoE patients, yearly dilations were required to maintain esophageal patency (31, 46). 
Our data suggest that dilation may often be needed at shorter intervals. The exact reason for 
multiple dilations is not clear, but possible explanations include failure of medical or dietary 
therapy, patient refusal or inability to tolerate chronic treatment, practice variation with 
dilation being performed more frequency at the index/diagnostic endoscopy, and referral 
patterns with EoE patients with more severe strictures being seen at our tertiary care center. 
Regardless of the reason, the need for multiple dilations in adult EoE patients is not 
necessarily unexpected. There is a known association between duration of symptoms and 
stricture formation (20, 23). From a mechanistic standpoint, both eosinophils and mast cells 
produce TGF-β, which in turn recruits fibroblasts, promotes epithelial mesenchymal 
transition, and increases smooth muscle contractility, all of which contribute to esophageal 
remodelling in EoE (15-17, 34, 37, 47-50). It is hypothesized that longstanding 
inflammation and ongoing fibrotic changes result in the phenotype of strictures, rings, and 
narrow caliber esophagus seen in adult patients (17, 20, 23, 51, 52). In our population with 
longstanding (>10 year) symptom duration prior to diagnosis, this may explain the frequent 
need for multiple dilations.
Few data are available to guide endoscopists on dilation technique (1, 3, 6, 53), and 
techniques used for dilation in EoE differ across centers, with some centers having a 
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preference for balloons (29, 33) and others preferring bougies (31, 36, 54, 55). Among 6 
recent large studies that have reported 1069 dilations in EoE patients, 37% were performed 
using balloon dilators, and 63% of which were performed using bougies (29, 31, 33, 36, 54, 
55). Some authors suggest using bougie dilators when complex strictures or diffuse 
narrowing are encountered (32, 52, 55, 56), but others advocate the size control and direct 
visualization afforded by TTS balloons (43, 57). Our data showed that both techniques were 
safe and effective. Given similar published safety and efficacy parameters and little 
comparative data on the two types of dilation, endoscopists are guided by the clinical 
circumstance, as well as likely their own preference and experience with dilation (36, 58). 
Future studies comparing specific dilation methods across a variety of clinical scenarios are 
needed to help further guide endoscopists treating strictures in EoE.
In terms of dilation efficacy, these methods significantly increased esophageal caliber and 
improved symptoms in 85% of cases in which follow-up information was available. This 
proportion is comparable to that reported in the literature, which ranges from 81% - 92% 
(29, 31, 33, 37). It is important to note, however, that esophageal diameter measurement 
were inferred from the dilator sizes used, and symptomatic improvement was graded as a 
yes/no dichotomous variable only. For safety, we had no major complications of bleeding 
perforation, or death, which is also consistent with recent literature (57, 59, 60). We also 
reported two hospitalizations following dilation, both due to aspiration pneumonia. 
Aspiration pneumonia is not necessarily a complication of dilation itself, but given the 
retrospective study design we could not distinguish if the pneumonia was due to the dilation 
or the endoscopy. A review on esophageal dilation in EoE found an overall perforation rate 
of 0.6% among all published studies, and a rate among recent studies of only 0.3% (58); 
similar rates were found in 2 meta-analyses (37, 38). One recent prospective trial of dilation 
also found no major complications (61). Of note, these figures are close to the overall rate of 
perforation from dilation quoted for any indication, 0.1-0.4% (53).
An issue that remains unanswered is the durability of esophageal dilation in EoE. Of patients 
in our study who required multiple dilations, a majority (75%) required repeat dilation 
within one year, and these patients were dilated a median of 4 months after their first 
dilation. The timeframe for repeat dilation among our patients is shorter than has been seen 
previously (31). The exact reason for this difference is not known, but possible explanations 
include differences in the dilation technique and target diameter for dilation, variability 
between endoscopists, incomplete control of inflammation, and patient phenotype. Other 
studies suggest that repeated dilations over an “induction” period are needed for patients 
with severe fibrostenotic EoE (55), and we employ a similar practice in patients with severe 
or diffuse esophageal strictures or narrowing. However, prospective studies examining the 
durability of dilation among distinct phenotypes of EoE patients would better practice.
Our study has several limitations. The first is its retrospective design. Information about 
esophageal caliber had to be inferred from the diameter of the endoscopic equipment used. It 
is possible that complications could have been under-reported due to the retrospective 
design, as our figures of post-procedure pain are lower than what have been previously 
reported. In addition, the retrospective design of our study limited our ability to know 
precisely what proportion of patients derived symptomatic improvement from dilation, and 
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to what degree a patient derived improvement in tolerance of solid foods. The coding of 
symptomatic improvement as a yes/no variable meant that we could not grade the degree of 
symptom relief. For those who were symptom responders, we could not entirely separate the 
effect of the dilation from the effect of concomitant pharmacologic or dietary treatment. 
However, in order to mitigate this effect we stratified response rates by therapy and found 
comparable symptom response rates regardless of whether there was concomitant anti-
inflammatory therapy or not, indicating dilation likely contributes significantly to 
symptomatic improvement in the patients we studied. Another possible limitation is the use 
of differing dilation techniques at our center. There was no standardized protocol for what 
type of dilator to use; instead, the type of dilator used was chosen at the discretion of the 
endoscopist, based on their preference and the clinical scenario. The balloon pull-through 
technique, utilized by some providers at our center, involves controlled withdrawal of an 
inflated balloon from the GEJ to the cricopharyngeus, done at increasing sizes until 
resistance and/or dilation effect are seen (43). This technique can involve reintubation of the 
esophagus in some cases, adding time to a procedure. In addition, any balloon-based dilation 
technique involves increased cost. In the future, comparative studies on dilation techniques 
could clarify if balloons or bougies are more effective in EoE. Finally, because of the 
specialized experience available at our center, it may be difficult to extrapolate the results to 
other practice setting, including those in the community, that are less familiar with dilation 
in EoE. However, even though approximately half of the dilations in this study were 
performed by the senior investigator (ESD), there were few major differences between 
patient, dilation, and outcome characteristics by provider.
These limitations are balanced by the strengths of this study which include a large and well-
characterized cohort of EoE patients, a comprehensive data extraction protocol with 
exhaustive follow-up information on the vast majority of individuals receiving dilation, and 
the largest yet reported series of esophageal dilation in EoE comprising sizable patient 
groups treated with both balloons and bougies.
In conclusion, our data show that esophageal dilation is a safe and effective treatment for 
relief of symptoms related to esophageal stricture, rings, or generalized narrowing in EoE 
patients. Approximately one third of EoE patients require dilation, with longer duration of 
symptoms being an important predictor. Notably, of those who do require dilation, more 
than half will require multiple dilations and typically in a short time frame, a new finding 
that can be used to counsel patients who are found to have fibrostenotic complications of 
EoE. Future studies could address the extent to which symptoms and diet can improve with 
esophageal dilation, the comparative effectiveness of different dilator types, and how anti-
inflammatory therapy following esophageal dilation may minimize the need for repeat 
dilation.
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Study Highlights
What is current knowledge?
• Patients with eosinophilic esophagitis may require esophageal dilation to treat 
symptoms of dysphagia due to esophageal strictures or narrowing
• Little is known about the long-term efficacy about dilation or predictors and 
frequency of requiring multiple dilations
What is new here?
• Approximately 1/3 of EoE patients required esophageal dilation, and of those 
requiring a single dilation almost 60% required multiple dilations, the majority 
of which were performed within a year.
• The only predictor of requiring multiple dilations was a smaller baseline 
esophageal diameter.
• Dilation was tolerated well, with no major bleeds or perforations.
• Bougie and through-the-scope balloon dilators performed similarly
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Figure 1. 
Temporality of repeat esophageal dilation in EoE. This graph shows the proportion of EoE 
patients who required repeat dilation in 6, 9, 12, and 18 months. The solid black line 
indicates the proportion who required a second dilation after their first procedure, and the 
dashed line indicates the proportion who required a third dilation after their second 
procedure.
Runge et al. Page 14
Am J Gastroenterol. Author manuscript; available in PMC 2017 February 01.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Runge et al. Page 15
Table 1
Characteristics of patients with eosinophilic esophagitis, comparing those requiring dilation to those not 
requiring dilation
No Dilation
(n = 345)
Dilation
( n = 164) p
*
Age at diagnosis (mean yrs ± SD; range) 20.7 ± 17.6
(0.6-73.5)
38.6 ± 15.2
(10.7-82.0)
<0.001
 Adults (≥ 18 year; n, %) 110 (36) 134 (91) < 0.001
Symptom length prior to diagnosis (mean yrs ± SD) 5.4 ± 6.8 11.1 ± 11.1 <0.001
Males, n (%) 251 (73) 112 (68) 0.30
White, n (%) 269 (79) 143 (89) 0.006
Symptoms, n (%)
 Dysphagia 186 (55) 157 (96) <0.001
 Food impaction 89 (27) 73 (49) <0.001
 Heartburn 144 (43) 45 (30) 0.007
 Chest pain 32 (10) 19 (13) 0.33
 Abdominal pain 95 (28) 13 (9) <0.001
 Vomiting 105 (32) 26 (17) 0.001
 Failure to thrive 54 (16) 3 (2) <0.001
EGD Findings, n (%)
 Normal 72 (21) 3 (2) <0.001
 Rings 107 (31) 118 (72) <0.001
 Stricture 11 (3) 82 (50) <0.001
 Narrowing 21 (6) 50 (30) <0.001
 Furrows 154 (45) 89 (54) 0.06
 Crepe-paper mucosa 15 (4) 8 (5) 0.81
 White plaques 89 (26) 49 (30) 0.38
 Erythema 27 (8) 10 (6) 0.46
 Decreased vascularity 73 (21) 42 (26) 0.30
 Erosive esophagitis 90 (26) 44 (27) 0.93
 Max eosinophil counts (mean eos/HPF ± SD) 79.1 ± 75 81.8 ± 77 0.71
SD, standard deviation; eos, eosinophils; HPF, high-power field
*
P values calculated using Student’s t-test for continuous variables and chi-squared test for categorical variables.
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Table 2
Efficacy and Safety of Dilation
Any Dilation
(n = 164)
Total number of dilations 486
Number of dilations per patient (mean ± SD) 3.0 ± 3.7
Dilation Method, n (%)
   Savary 91 (19)
   Balloon 395 (81)
Esophageal diameter (mm) before dilation (mean ± SD) 12.5 ± 3.0
Esophageal diameter (mm) after final dilation (mean ± SD) 15.2 ± 2.9
Increase in esophageal diameter (mean mm ± SD) 2.6 ± 1.4
Symptom response, n (%)‡ 108 (87)
Complications, n (%)
   Any complication 25 (5.1)
   Pain 21 (4.3)
   Bleeding 0 (0)
   ER visit 5 (1.0)
   Hospitalization 2 (0.4)
   Perforation 0 (0)
   Death 0 (0)
‡Symptom response data available for n=124
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Table 3
Characteristics and Performance of Dilation, by Type of Dilator Used
Balloon
(n = 395)
Savary
(n = 91)
p
Max eosinophil count (mean eos/hpf ± SD) 55.8 ± 53.5 58.7 ± 72.2 0.73
On meds at dilation, n (%) 162 (42) 29 (34) 0.19
On diet at dilation, n (%) 60 (16) 13 (18) 0.90
Esoph diameter (mm) before dil (mean ± SD) 12.5 ± 2.9 12.7 ± 3.6 0.55
Esoph diameter (mm) after dil (mean ± SD) 15.3 ± 2.9 14.5 ± 2.7 0.02
Increase in esoph diameter (mean mm ± SD) 2.8 ± 1.2 1.8 ± 1.5 <0.001
Symptom response, n (%)* 106 (87) 24 (77) 0.34
Complications, n (%)‡
   Any complication 16 (4) 9 (10) 0.10
   Pain 16 (4) 5 (6) 0.53
   Bleeding 0 0 N/A
   ER visit 1 (0.3) 4 (4) 0.005
   Hospitalization 1 (0.3) 1 (1.1) 0.34
   Perforation 0 0 N/A
   Death 0 0 N/A
*Symptom response data available for n= 153 individual dilations)
‡
More than one complication (i.e., pain followed by er visit) occurred following a single dilation in n=6 cases.
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Table 4
Comparison of EoE Patients Requiring One Dilation to those requiring Multiple Dilations
Single Dilation
(n = 69)
Multiple Dilations
(n = 95)
p
Age at diagnosis (mean yrs ± SD) 39.0 ± 16.4 38.2 ± 14.3 0.74
Symptom length prior to dx (mean yrs ± SD) 9.4 ± 10.7 12.2 ± 11.2 0.18
Males, n (%) 49 (71) 63 (66) 0.52
White, n (%) 58 (85) 85 (91) 0.23
Symptoms, n (%)
   Dysphagia 65 (94) 92 (98) 0.22
   Food impaction 30 (49) 43 (48) 0.92
   Heartburn 23 (38) 22 (25) 0.09
   Chest pain 8 (13) 11 (12) 0.92
   Abdominal pain 7 (11) 6 (7) 0.34
   Failure to thrive 1 (2) 2 (2) 1
   Food allergies 11 (22) 19 (23) 0.91
   Any atopic disease 21 (34) 38 (43) 0.31
Endoscopic findings at baseline, n (%)
   Rings 49 (71) 69 (73) 0.82
   Narrowing 17 (25) 33 (35) 0.17
   Stricture 30 (44) 52 (55) 0.16
   Linear furrows 39 (56) 50 (53) 0.62
   White plaques 21 (30) 28 (29) 0.89
   Decreased vascularity 18 (26) 24 (25) 0.91
Max eosinophil count (mean eos/HPF ± SD) 76.3 ± 59.5 85.7 ± 87.5 0.44
Histologic response (% <15 eos/HPF), n (%)* 17 (57) 32 (48) 0.42
Dilation Method, n (%)‡
   Savary 12 (18) 32 (34) 0.03
   Balloon 57 (82) 87 (93) 0.05
Esoph diameter (mm) before dilation (mean ± SD) 12.5 ± 2.8 11.3 ± 2.9 0.01
Esoph diameter (mm) after dilation (mean ± SD) 15.7 ± 3.0 16.2 ± 2.4 0.30
Esoph diameter (mm) increase (mean ± SD) 3.0 ± 1.3 4.9 ± 2.5 <0.001
*
Post-dilation biopsy information available for n=97 individuals
‡
Proportions total >100% as some individuals (n=25) underwent procedures using both types of dilators
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